Lee Rodne, CEO of LTR Pharma, Discusses His Company's New Nasal Spray Formulation for ED

LTR's new drug, Spontan, is a “first-in-class” rapid onset, on-demand therapeutic nasal spray for the treatment of ED. The company is nearing commercialization and just completed a successful capital raise that will propel the drug into Australian and US markets in the near future.
Here is my write-up on LTR Pharma simonschase.co... This is not investment advice. Do not rely on the contents of this video. Do your own due diligence.

[@blackpanthercycling3000]

Great interview Simons.

[@vanguardrobotics4114]

This looks fantastic. Great informative video. I am looking forward to seeing this in the market soon.

[@markfergusson-ed4uz]

What is to stop competitors copying the product? What are the details of the supply agreement with maker of drug in Spontan, is it exclusive supply agreement?

[@blackpanthercycling3000]

1. Patents filed gives the company protection 2. Vardenafil a generic drug produced by numerous suppliers so supply is not an issue